Other efforts to treat PKAN include supplementation with CoA, pantethine, P-PaSH, and acetyl-P-PaSH (13, 50, 51, 52) to compensate for the reduced levels of the metabolic intermediates of CoA caused by altered Pank2 activity. The gene discussed is PANK2; the disease is pantothenate kinase-associated neurodegeneration.